SCHEMBL23002255

SCHEMBL23002255

CC1CCCN(Cc2cc(C(=O)Nc3cccc(C4(Cc5nncn5C)CC(C#N)C4)c3)nc(C3CC3)c2)C1

nearest known ligand 0.66

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ CBLB Q13191 20/20 0.66
▸ CBLC Q9ULV8 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23002254 1.00 CBLB (0.66) CBLBCBLC
SCHEMBL22695611 1.00 CBLB (0.66) CBLBCBLC
SCHEMBL29535765 1.00 CBLB (0.66) CBLBCBLC
SCHEMBL25246786 0.94 CBLB (0.69) CBLBCBLC
SCHEMBL22695613 0.94 CBLB (0.69) CBLBCBLC
SCHEMBL29536093 0.94 CBLB (0.69) CBLBCBLC
SCHEMBL23002302 0.90 CBLB (0.67) CBLBCBLC
SCHEMBL22695607 0.90 CBLB (0.67) CBLBCBLC
SCHEMBL23002304 0.90 CBLB (0.67) CBLBCBLC
SCHEMBL29535944 0.90 CBLB (0.67) CBLBCBLC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240409555-A1 CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF NURIX THERAPEUTICS, INC. 2024-12-12 — — US disclosed
US-12049471-B2 Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof NURIX THERAPEUTICS, INC. (US) 2024-07-30 — — US disclosed
US-20230212186-A1 CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF NURIX THERAPEUTICS, INC. 2023-07-06 — — US disclosed
US-11530229-B2 Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof NURIX THERAPEUTICS, INC. (US) 2022-12-20 — — US disclosed
CN-114206855-A Cyanocyclobutyl compounds for Cbl-b inhibition and uses thereof 紐力克斯治疗公司 2022-03-18 — — CN disclosed
US-20210053986-A1 CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF NURIX THERAPEUTICS, INC. 2021-02-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12049471-B2 Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof CBLB, CBL, CBLC CBLB 1/4885CBLC 3/4885
US-20210053986-A1 CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF CBLB, CBL, CBLC CBLB 1/4885CBLC 3/4885
US-20240409555-A1 CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF CBLB, CBL, CBLC CBLB 1/4885CBLC 3/4885
US-11530229-B2 Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof CBLB, CBL, CBLC CBLB 1/4885CBLC 3/4885
US-20230212186-A1 CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF CBLB, CBL, CBLC CBLB 1/4885CBLC 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback